within Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX25_Mizolastine;

model Mizolastine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.65,
    Cl = 2.861111111111111e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.04,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.012833333333333334,
    Tlag = 13.2);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Mizolastine</td></tr><tr><td>ATC code:</td><td>R06AX25</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Mizolastine is a second-generation non-sedating antihistamine used to treat allergic rhinitis and urticaria. It works by selectively antagonizing peripheral H1 histamine receptors, reducing allergic symptoms. The drug is approved and used in several countries, though not available in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after oral single-dose administration.</p><h4>References</h4><ol><li><p>Lebrun-Vignes, B, et al., &amp; Chosidow, O (2001). Clinical pharmacokinetics of mizolastine. <i>Clinical pharmacokinetics</i> 40(7) 501–507. DOI:<a href=\"https://doi.org/10.2165/00003088-200140070-00002\">10.2165/00003088-200140070-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11510627/\">https://pubmed.ncbi.nlm.nih.gov/11510627</a></p></li><li><p>Li, P, et al., &amp; Zhang, GL (2018). Effects of UGT1A1, CYP3A5 and ABCB1 Genetic Variants on Pharmacokinetics of Antihistamine Drug Mizolastine in Chinese Healthy Volunteers. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 123(4) 464–473. DOI:<a href=\"https://doi.org/10.1111/bcpt.13028\">10.1111/bcpt.13028</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29702735/\">https://pubmed.ncbi.nlm.nih.gov/29702735</a></p></li><li><p>Simons, FE (2002). Comparative pharmacology of H1 antihistamines: clinical relevance. <i>The American journal of medicine</i> 113 Suppl 9A 38S–46S. DOI:<a href=\"https://doi.org/10.1016/s0002-9343(02)01436-5\">10.1016/s0002-9343(02)01436-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12517581/\">https://pubmed.ncbi.nlm.nih.gov/12517581</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R06AX25 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Mizolastine;
